The way patients and their families often describe plasma-derived medicines speaks volumes. We have heard:.❝ Lifesaving.❝ Life-changing.❝ What gives me my energy back.❝ The only treatment I have.❝ A gift . What one word would you choose to capture that impact? 👇

Did you know? Germany, Austria, Hungary & Czechia are leading in plasma collection in Europe. 50% of all plasma used to manufacture plasma-derived medicines comes from these four countries. Learn more:

Learn how #PlasmaPowersPossibility at a PPTA & @Euractiv event in #Brussels just ahead of #IPAW2025.

Ahead of #IPAW2025, attend an informative panel discussion in #Brussels alongside PPTA and @Euractiv. This event brings together key stakeholders to exchange views and proposals on strengthening medicines supply chains and safeguarding uninterrupted patient access across the EU.

Did you know that plasma-derived medicines cannot be used interchangeably? Physicians need to do complex evaluations to determine the appropriate brand, dosage & administration route for patients. Learn more:

50% of all source donated plasma in Europe is given by donors in only four countries: Austria, Czech Republic, Germany and Hungary, who mainly use plasmapheresis. Learn more:

The process of manufacturing plasma-derived medicinal products (PDMPs) takes much longer to produce than chemically-synthesized pharmaceutical medicines. It may take up to 12 months to manufacture PDMPs, from the moment the donation is made until it is ready to be given to a

The use of immunoglobulin (IG) treatments nearly doubled between 2009 and 2019. Check out some key factors driving the increased clinical need for plasma-derived medicines. 👇. #EUNeedsMorePlasma.

June 28 is #InternationalNeonatalScreeningDay. PPTA proudly joins global efforts to raise awareness about the importance of neonatal screening programmes to address the unmet needs of children born with rare and treatable diseases. 📅 #INSD.🔗 Visit:

A few weeks have passed since we gathered in Warsaw for #IPPC2025. If you missed it or want to revisit the highlights, our latest blog recaps the key takeaways and moments that made this 20th edition special. Catch up here:

The European Plasma Alliance (EPA) just released a statement on Czechia's new national plasma donor registry. Learn how this initiative supports donor safety and what EPA recommends moving forward.

Life-saving plasma-derived medicines keep patients healthy & active, contributing to a more productive society for everyone. Consistent access is critical as patient clinical needs grow. Learn more:.

PPTA is pleased to announce the appointment of @marilenavrana as Vice President, Public Affairs & EU Operations. Marilena, who has led our EU Public Affairs since 2022, officially began her new role on 2 June. Read the full announcement below. ⬇️.

Plasma-derived medicines are often the ONLY treatment for #rare diseases. Without access, patients risk: .▪️ Serious health complications .▪️ Physical limitations .▪️ Social isolation .▪️ Reduced quality of life . Access to these #lifesaving treatments .is CRITICAL!⬆️

PPTA acknowledges EDQM's 22nd "Blood Guide" which offers key guidance on blood components. We commend EDQM's efforts for donor & patient safety but believe greater clarity on source plasma donation for fractionation would be beneficial.

It's not too late to share your IPPC experience on social media! Use the official event hashtags #IPPC2025 or #20YearsIPPC on a social media recap post for a chance to win a gift card!

On 22 May, members of the PPTA Europe team met with Patricia Reilly, member of the office of @vonderleyen, the President of the @EU_Commission. During the conversation, PPTA highlighted the industry’s strong economic footprint in Europe, as well as the uniqueness of the